Pacira生物科学 PCRX 深 沪
已收盘 04-02 16:00:00 美东时间
22.70
-0.090
-0.39%
华盛通- 最 高22.925
- 今 开22.40
- 成交量 75.04万股
- 最 低 22.185
- 昨 收 22.79
- 总市值 9.19亿
- 52周最高 27.64
- 市盈率 静 145.33
- 换手率 1.85%
- 52周最低 18.80
- 委 比 -14.41%
- 总股本 4048.99万
- 历史最高 121.95
- 量 比 1.40
- 振 幅 3.25%
- 历史最低 6.51
- 每 手 1
- 风险率 1.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $25
Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight and lowers the price target from $27 to $25.
03-26 20:46
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining in pre-market trading.
03-25 20:02
BUZZ-U.S. STOCKS ON THE MOVE-SciSparc, Natera, US energy companies
BUZZ-U.S. STOCKS ON THE MOVE-SciSparc, Natera, US energy companies Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 12 (Reuters) - Wall Street's main indexes were set to ope
03-12 21:20
DOMA Perpetual Asserts Pacira BioSciences CEO Frank Lee Should Be Replaced Immediately; Urges Board To Name Interim CEO And Conduct Formal Sale Process Of The Business
Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30%ii; The Company's Underperformance is Reflected in
03-12 01:11
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
Pacira BioSciences confirmed DOMA's nomination of three director candidates for the 2026 Annual Meeting. The Board reaffirmed its commitment to the 5x30 strategy, highlighting progress in patient treatments, EXPAREL growth, IP milestones, gross margin improvement, clinical advancements, and commercial collaborations. The company repurchased $150 million in shares in 2025. Despite 12 meetings with DOMA since Frank Lee became CEO in 2024, no new in...
03-11 21:02
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted inducement awards to three new employees on March 3, 2026, under its 2014 Inducement Plan, approved by the People & Compensation Committee. One employee received 2,400 stock options with a $22.10 exercise price and a 10-year term, vesting over four years. Three employees received 5,500 restricted stock units, vesting annually over four years. Pacira offers non-opioid pain solutions, including EXPAREL, ZILRETTA, and ...
03-06 13:00
Pacira BioSciences Presents Real-World Evidence From Innovations In Genicular Outcomes Registry At AAOS 2026 Annual Meeting
-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee ---- Data presented at the American
03-02 21:13
Pacira Presents IGOR Real-World Studies Highlighting EXPAREL and iovera Knee Pain Benefits at AAOS 2026
Pacira Presents IGOR Real-World Studies Highlighting EXPAREL and iovera Knee Pain Benefits at AAOS 2026 Pacira BioSciences reported real-world evidence from its Innovations in Genicular Outcomes Registry (IGOR), including two observational studies in knee osteoarthritis and total knee arthroplasty p
03-02 21:02
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
Pacira BioSciences presented real-world evidence from the IGOR registry at the 2026 AAOS Annual Meeting, highlighting EXPAREL's clinical effectiveness for total knee arthroplasty and long-term pain management with iovera° for knee osteoarthritis. The studies demonstrated improved pain, opioid use, function, and recovery outcomes with EXPAREL, while iovera° provided sustained pain relief for up to 12 months. These findings aim to inform evidence-b...
03-02 13:00
